This Viewpoint discusses newer antiobesity medications that hold promise and how uneven access to these medications could exacerbate obesity disparities.

Me gusta

Guardar

Ver artículo completo

Me gusta

Guardar

Ver artículo completo

Cite This Study

Wright et al. (Fri,) studied this question.

synapsesocial.com/papers/6a2311235bf42efd08cb3585 https://doi.org/https://doi.org/10.1001/jamahealthforum.2023.0493

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Distributional Cost-Effectiveness Analysis2020 · 83 citations
2Prevalence of Obesity Among Adults, by Household Income and Education — United States, 2011–20142017 · 468 citations
3Impact of Real-Time Benefit Tools on Patients’ Access to Medications: A Retrospective Cohort Study2022 · 10 citations
4Cost-Effectiveness in Health and Medicine2016 · 1,558 citations
5Managing Obesity: Scaling the Pyramid to Success2019 · 5 citations

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Distributional Cost-Effectiveness Analysis2020 · 83 citations
2Prevalence of Obesity Among Adults, by Household Income and Education — United States, 2011–20142017 · 468 citations
3Impact of Real-Time Benefit Tools on Patients’ Access to Medications: A Retrospective Cohort Study2022 · 10 citations
4Cost-Effectiveness in Health and Medicine2016 · 1,558 citations
5Managing Obesity: Scaling the Pyramid to Success2019 · 5 citations